 |
 |
.NEWS FROM SIO
Continue Accessing the SIO2021 Platform
SIO
Thank you again for attending the SIO2021 Annual Scientific Meeting! As a reminder, your registration provides continued access to all virtual platform content through 6 April 2021. Remember to claim your CME credit, and continue exploring SIO member benefits.
REVIEW RECORDINGS NOW
|
|
Renew Your Membership to SIO and Unlock Full Member Benefits
SIO
An SIO membership provides you with numerous personal and professional benefits, resources for growth and support, access to the latest science, and more!
Renew your membership today, and look forward to:
- Learning about the latest NCCN guideline updates as they are submitted by Society leadership.
- Applying for and serving on SIO member-only committees.
- Connecting with more than 600 professionals from around the world in order to expand your network and further your career.
- Receiving discounted registration to SIO's Annual Scientific Meeting and additional educational events.
- The opportunity to apply for and receive exclusive, member-only grant and scholarship opportunities.
- Access to timely, relevant education materials and IO-specific resources.
- Gaining the latest society and industry updates from SIO publications.
- Earning continuing education credit from online courses, webinars, podcasts, and on-demand Annual Meeting recordings.
RENEW NOW
|
|
|
|
 |
|
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.
|
|
|
.INDUSTRY NEWS
|
|
| |
Promoted by AngioDynamics
 DIRECT, a clinical study evaluating the effectiveness of IRE technology on stage III pancreatic cancer, is actively enrolling patients. DIRECT, initiated by AngioDynamics, is led by Co-Principal Investigators – Govindarajan Narayanan, MD, Chief of Interventional Oncology at Miami Cancer Institute and Robert C.G. Martin, MD, PhD, Surgical Oncology at the University of Louisville. Visit AngioDIRECT.com to learn more.
|
|
|
In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
DocWire News
Prostate cancer is one of the most common malignancies worldwide, yet limited tools exist for prognostic risk stratification of the disease. Identification of new biomarkers representing intrinsic features of malignant transformation and development of prognostic imaging technologies are critical for improving treatment decisions and patient survival.
|
|
|
|
|
|
